Core Insights - Yangzhou is recognized as a city of canals, cuisine, and culture, showcasing its historical and commercial value through the World Canal Historical and Cultural Cities Cooperation Organization (WCCO) and its media platform, Dayunhe Media [1] - The latest Hurun Rich List highlights the top ten wealth creators in Yangzhou for 2025, emphasizing the entrepreneurial spirit and innovative capabilities of local business leaders [1] Group 1: Top Wealth Creators - The richest individual is Liang Qin, Chairman of Yangjie Electronics Technology, with a net worth of 16 billion yuan, ranking 411th nationally. The company has evolved from a trading firm to a leading IDM model enterprise in power semiconductors [1] - Zhu Daqing, Chairman of Tianfulong Group, ranks second with a net worth of 13 billion yuan, marking his debut on the Hurun Rich List. The company is a leader in differentiated polyester short fibers, focusing on "technology innovation + green transformation" [3] - Zhu Yinghui, holding 36.17% of Rongtai Co., ranks third with a net worth of 5.5 billion yuan. The company specializes in precision die-casting for automotive lightweight components [4] - Zhou Guangrong, Chairman of Haichang New Materials, has a combined net worth of approximately 5.3 billion yuan with his wife. The company is a leader in the powder metallurgy industry, particularly in electric tool components [6] - Li Hongqing, former actual controller of Jiangsu Aoliwei Sensor, has a net worth of at least 3.8 billion yuan, focusing on automotive parts and sensors [8] - Fu Helian, Chairman of Aidi Pharmaceutical Group, has a net worth of 3.8 billion yuan, leading a company that specializes in innovative drugs for major diseases [10] - Zou Weimin, Chairman of Chuan Yi Technology, has a net worth of approximately 3.1 billion yuan, focusing on computer keyboards and control panels [12] - Zhang Wensheng, Chairman of Beijiajie Group, has a net worth of about 2.4 billion yuan, specializing in oral care and hygiene products [13] - Zhu Xingrong, General Manager of Tianfulong Group, is the youngest on the list at 2.3 billion yuan, holding 13.14% of the company's shares [15] - Lin Mingwen, Chairman of Yangzhou Jinqian Tourism Products, has a net worth of approximately 1.5 billion yuan, focusing on outdoor products [16] Group 2: Entrepreneurial Insights - Over half of the top ten wealth creators started from grassroots sales or technical positions, demonstrating their ability to seize opportunities during industry transformations [16]

证券代码：688488 证券简称：艾迪药业 公告编号：2026-011 江苏艾迪药业集团股份有限公司 关于 ADC205 片获得药物临床试验批准通知书的 自愿性披露公告 一、通知书基本情况 药品名称：多替拉韦拉米夫定替诺福韦片 受理号：CXHL2501238 申请事项：境内生产药品注册临床试验 申请人：江苏艾迪药业集团股份有限公司 通知书编号：2026LP00163 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 11 日受理的多替拉韦拉米夫定替诺福韦片临床试验申请符合药品注册的 有关要求，同意本品开展作为一个完整的治疗方案适用于治疗患有人类免疫缺陷 病毒 1 型（HIV-1）感染的成人和体重 35kg 或以上的儿童患者的临床试验。 二、药品相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）收到国家药品监督管 理局（以下简称"国家药监局"）于 2026 年 1 月 18 日核准签发的《药物临床试 验批准通知书》（以下简称"通知书" ...

本品组方内的3种有效成分均已作为单药上市并用于艾滋病治疗多年，作用机制明确。目前，以拉米夫 定（3TC）、富马酸替诺福韦二吡呋酯（TDF）为骨干，多替拉韦（DTG）为核心的抗逆转录病毒治疗 方案（ART）具有抗病毒疗效高、抑制病毒速度快等优点，世界卫生组织指南（2021）、欧洲艾滋病临 床协会指南（2024）、美国卫生及公共服务部指南（2024）、美国国际抗病毒协会指南（2024）以及 《中国艾滋病诊疗指南（2024版）》等国内外权威指南均将该三药联用方案列为HIV人群的推荐治疗方 案之一。 多替拉韦拉米夫定替诺福韦片（以下简称"本品"）是由公司开发的用于治疗HIV-1感染的化学药品2.3类 复方制剂，其组份为：每片含多替拉韦钠（按C20H19F2N3O5计）50mg，拉米夫定300mg，富马酸替诺 福韦二吡呋酯300mg，拟作为一个完整的治疗方案适用于治疗患有人类免疫缺陷病毒1型（HIV-1）感染 的成人和体重35kg或以上的儿童患者。 格隆汇1月19日丨艾迪药业(688488.SH)公布，公司收到国家药品监督管理局于2026年1月18日核准签发 的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3 ...

每经AI快讯，1月19日，艾迪药业公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批 准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药多替拉韦拉米夫定替诺福韦片(ADC205片)开 展临床试验。 ...

| 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 | 当日涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | | 688488 | 艾迪药 业 | 27783.57 | 74.10 | 2.96 | 医药生物 | | 601799 | 星宇股 份 | 29085.74 | 49.50 | -1.15 | 汽车 | | 920580 | 科创新 材 | 872.49 | 43.70 | 5.42 | 建筑材料 | | 301266 | 宇邦新 材 | 18848.82 | 43.38 | 17.20 | 电力设备 | | 600744 | 华银电 力 | 24596.97 | 42.75 | 7.98 | 公用事业 | | 002707 | 众信旅 游 | 53240.43 | 42.12 | -8.47 | 社会服务 | | 688548 | 广钢气 体 | 27349.12 | 38.29 | 10.50 | 电子 | | 301021 | 英诺激 光 | 34100.29 | 37.36 | ...

Core Viewpoint - Eddy Pharmaceutical (688488) has seen a significant stock price increase of 22.17% this week, closing at 21.6 yuan, with a market capitalization of 9.089 billion yuan as of January 16, 2026 [1] Trading Information Summary - Eddy Pharmaceutical reached a maximum price of 22.11 yuan on January 16, 2026, marking a near one-year high, and was listed on the Shanghai and Shenzhen Stock Exchanges' "Dragon and Tiger List" due to a price increase of 15% on January 14, 2026 [1][4] - The company’s Vice President Wang Guangrong, Yu Ke, and non-independent director Liu Yan faced regulatory measures from the Shanghai Stock Exchange for information disclosure violations [1][4] Company Announcement Summary - On January 13, 2026, Eddy Pharmaceutical's board approved a plan to issue A-shares to specific investors, aiming to raise no more than 185 million yuan for acquiring a 22.2324% stake in Nanjing Nanda Pharmaceutical and for supplementing working capital [1][4] - The company plans to acquire the minority stake in Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [2][4] - The board also decided to terminate the previous plan for a 2024 A-share issuance to specific investors [1][5] Fundraising and Financial Strategy - The total amount to be raised from the new issuance is capped at 185 million yuan, with 130 million yuan allocated for the acquisition and 55 million yuan for working capital [3][6] - The company has outlined a three-year shareholder dividend plan, committing to distribute at least 10% of the annual distributable profits in cash, with a cumulative cash dividend of no less than 30% of the average distributable profits over the past three years [2]

Group 1 - Eddie Pharmaceuticals' stock price increased by 5.15% on January 16, reaching 22.06 CNY per share, with a trading volume of 520 million CNY and a turnover rate of 6.05%, resulting in a total market capitalization of 9.282 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 24.14% during this period [1] - The company, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived proteins 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceuticals, the Xingsheng Global Fund has a fund that entered the top ten in the third quarter, holding 6.229 million shares, which accounts for 1.48% of the circulating shares [2] - The estimated floating profit for today is approximately 6.7273 million CNY, with a total floating profit of 25.4142 million CNY during the three-day increase [2] - The Xingsheng Global Fund's mixed fund (LOF) A (163415) was established on December 18, 2012, with a latest scale of 14.567 billion CNY, yielding 6.54% this year, ranking 2504 out of 8847 in its category, and 48.84% over the past year, ranking 2241 out of 8094 [2]

Core Insights - The economic vitality of Yangzhou has surged since the reform and opening-up, with a significant rise in private entrepreneurs who have created notable business legends [1] - The total wealth of the top ten billionaires in Yangzhou has reached 56.1 billion RMB, with two individuals surpassing 10 billion RMB and two newcomers making their debut on the list [1] Group 1: Top Billionaires - The richest individual is Liang Qin, chairman of Yangjie Electronics Technology, with a net worth of 16 billion RMB, ranking 411th nationally [4] - Zhu Daqing, chairman of Tianfu Long Group, ranks second with a net worth of 13 billion RMB, marking his first appearance on the list [7] - Zhu Yinghui, holding 36.17% of Rongtai Co., ranks third with a net worth of 5.5 billion RMB, also making her debut on the list [8] Group 2: Notable Achievements - Zhou Guangrong, chairman of Haichang New Materials, has a combined net worth with his wife of approximately 5.3 billion RMB, leading a prominent powder metallurgy company [10] - Fu Helian, chairman of Aidi Pharmaceutical Group, is the highest-educated billionaire on the list, focusing on innovative drug development [11] - Zou Weimin, chairman of Chuan Yi Technology, has a net worth of about 3.1 billion RMB, having established a successful company in the notebook industry [12] Group 3: Emerging Entrepreneurs - Li Hongqing, former actual controller of Aoliwei Sensor, has a net worth of at least 3.8 billion RMB, having taken control of the company through capital operations [14] - Zhang Wensheng, chairman of Beijiajie Group, has a net worth of around 2.4 billion RMB, having built a leading company in oral care products [15] - Lin Mingwen, chairman of Yangzhou Jinqiu Tourism Products, has a net worth of approximately 1.5 billion RMB, becoming a major player in outdoor equipment manufacturing [17] Group 4: Young Entrepreneurs - Zhu Xingrong, general manager of Tianfu Long Group and the youngest billionaire at 42, holds a 13.14% stake in the company with a net worth of about 2.3 billion RMB [19] - Over half of the top ten billionaires started from grassroots sales or technical positions, demonstrating their ability to seize opportunities in industry transformation [19]

Core Viewpoint - Jiangsu Aidi Pharmaceutical (688488.SH) announced a plan to acquire minority shareholder equity in its subsidiary, Nanjing Nanda Pharmaceutical, which will increase its direct shareholding from 51.13% to 73.36% [1][3] Group 1: Acquisition Details - Aidi Pharmaceutical plans to raise up to 185 million yuan through a simplified procedure to fund the acquisition, with 130 million yuan allocated for acquiring 22.23% of Nanda Pharmaceutical's equity and 55 million yuan for working capital [1] - The acquisition is expected to enhance Aidi's control over Nanda Pharmaceutical and optimize financial performance, maximizing synergies between the two companies [4][10] Group 2: Market Potential - The demand for stroke treatment is anticipated to surge, with acute ischemic stroke cases in China projected to rise from 4.1 million in 2023 to 4.9 million by 2027 [4] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035 [4] Group 3: Product Pipeline - Aidi's new drugs, AD108 injection and ADB116 injection, are positioned to become significant profit growth drivers, targeting acute ischemic stroke treatment [4] - Aidi's HIV drug, Enomirac, has shown strong sales potential, with revenue from HIV drugs reaching 211 million yuan in the first three quarters of 2025, a 57.12% increase year-on-year [6][7] Group 4: International Expansion - Aidi Pharmaceutical is accelerating its international market expansion, with its HIV drug Enomirac approved for sale in Zanzibar, marking a significant milestone for Chinese-developed HIV drugs in Africa [9] - The company is also advancing its pipeline of innovative drugs, including a new HIV integrase inhibitor and long-acting pre-exposure prophylaxis drugs, which are in various stages of clinical trials [10]

Group 1 - The core point of the article is that Jiangsu Aidi Pharmaceutical Group announced a plan to raise up to 185 million yuan through a simplified procedure for issuing A-shares, primarily to acquire a 22.23% stake in its subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. for approximately 130.06 million yuan and to supplement working capital with 55 million yuan [1][2] - The chairman of Aidi Pharmaceutical, Fu Helian, stated that this move is a significant step towards focusing on the core business and enhancing competitive strength, aimed at long-term strategic development [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, being one of the few companies in China that holds production licenses for both raw materials and injectable formulations [1] Group 2 - Aidi Pharmaceutical previously acquired a 19.96% stake in Nanda Pharmaceutical in July 2022 and plans to further purchase an additional 31.16% stake in 2024, thereby gaining control over Nanda Pharmaceutical [2] - The acquisition of the additional 22.23% stake will enhance Aidi Pharmaceutical's control over Nanda Pharmaceutical, promoting strategic management upgrades and improving financial performance [2] - Aidi Pharmaceutical has maintained rapid growth in the HIV treatment sector for three consecutive years and is focused on advancing its core research pipeline and establishing a comprehensive commercialization system for new HIV drugs [2]